Cargando…
P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430521/ http://dx.doi.org/10.1097/01.HS9.0000846552.63695.9d |
| _version_ | 1784779792919298048 |
|---|---|
| author | Martínez-López, J. Moreau, P. Usmani, S. Z. Garfall, A. van de Donk, N. W. San-Miguel, J. F. Oriol, A. Chari, A. Karlin, L. Mateos, M.-V. Popat, R. Nooka, A. K. Sidana, S. Trancucci, D. Verona, R. Girgis, S. Uhlar, C. Stephenson, T. Banerjee, A. Krishnan, A. |
| author_facet | Martínez-López, J. Moreau, P. Usmani, S. Z. Garfall, A. van de Donk, N. W. San-Miguel, J. F. Oriol, A. Chari, A. Karlin, L. Mateos, M.-V. Popat, R. Nooka, A. K. Sidana, S. Trancucci, D. Verona, R. Girgis, S. Uhlar, C. Stephenson, T. Banerjee, A. Krishnan, A. |
| author_sort | Martínez-López, J. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430521 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94305212022-08-31 P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 Martínez-López, J. Moreau, P. Usmani, S. Z. Garfall, A. van de Donk, N. W. San-Miguel, J. F. Oriol, A. Chari, A. Karlin, L. Mateos, M.-V. Popat, R. Nooka, A. K. Sidana, S. Trancucci, D. Verona, R. Girgis, S. Uhlar, C. Stephenson, T. Banerjee, A. Krishnan, A. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430521/ http://dx.doi.org/10.1097/01.HS9.0000846552.63695.9d Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Martínez-López, J. Moreau, P. Usmani, S. Z. Garfall, A. van de Donk, N. W. San-Miguel, J. F. Oriol, A. Chari, A. Karlin, L. Mateos, M.-V. Popat, R. Nooka, A. K. Sidana, S. Trancucci, D. Verona, R. Girgis, S. Uhlar, C. Stephenson, T. Banerjee, A. Krishnan, A. P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title | P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_full | P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_fullStr | P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_full_unstemmed | P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_short | P921: UPDATED EFFICACY AND SAFETY RESULTS OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 |
| title_sort | p921: updated efficacy and safety results of teclistamab, a b-cell maturation antigen x cd3 bispecific antibody, in patients with relapsed/refractory multiple myeloma from majestec-1 |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430521/ http://dx.doi.org/10.1097/01.HS9.0000846552.63695.9d |
| work_keys_str_mv | AT martinezlopezj p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT moreaup p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT usmanisz p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT garfalla p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT vandedonknw p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT sanmigueljf p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT oriola p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT charia p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT karlinl p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT mateosmv p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT popatr p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT nookaak p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT sidanas p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT trancuccid p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT veronar p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT girgiss p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT uhlarc p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT stephensont p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT banerjeea p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 AT krishnana p921updatedefficacyandsafetyresultsofteclistamababcellmaturationantigenxcd3bispecificantibodyinpatientswithrelapsedrefractorymultiplemyelomafrommajestec1 |